WEST SACRAMENTO, Calif. — Gemini Bioproducts, LLC has launched aiMOS, an artificial intelligence–enabled media optimization service developed in collaboration with Tolemy Bio, aimed at improving the performance, consistency, and scalability of cell therapy manufacturing.
The new service uses artificial intelligence and machine learning combined with multi-omics data to design custom media supplements tailored to specific cell therapy processes. GeminiBio said aiMOS is intended to help developers improve critical quality attributes, increase manufacturing efficiency, and reduce overall costs across T-cell, NK-cell, TCR, and tumor-infiltrating lymphocyte development and manufacturing.
GeminiBio supplies serum, customized media, buffers, and process liquids to biopharma and advanced therapy companies working in areas such as mRNA, AAV, monoclonal antibodies, and cell therapies. For more than a decade, the company’s human AB serum has been widely used to support immune cell expansion in both clinical development and commercial manufacturing. According to the company, aiMOS represents a shift from generalized supplementation toward data-driven, process-specific media optimization that enhances a customer’s existing base media.
“Cell therapy developers shouldn’t have to accept one-size-fits-all media when their processes, cell sources, and activation strategies are so different,” said Brian Parker, Chief Executive Officer at GeminiBio. “aiMOS reads what the cells are telling us in culture, designs a tailored media supplement, and then takes that formulation all the way to cGMP—so developers can improve CQAs, reduce batch variability, and lower cost per dose without disrupting their base media choice.”
The service applies causal AI modeling to analyze cellular metabolic and behavioral data, with the goal of identifying factors that influence potency, yield, and overall performance. Based on these insights, the platform predicts supplement compositions and concentrations designed to enhance cell performance, while leveraging GeminiBio’s cGMP manufacturing and custom filling capabilities to support scale-up.
“By applying causal AI modelling to a cell’s metabolic and behavioral fingerprints, our platform can identify the exact levers that drive cell therapy performance, potency and yield,” said Alex Ward, PhD, co-founder of Tolemy Bio. “Paired with GeminiBio’s cGMP manufacturing and custom filling capabilities, aiMOS gives cell therapy developers a practical, high-impact way to achieve better performance—with full confidence to scale from early development through commercialization.”
GeminiBio said aiMOS is designed to help developers improve viable cell yields, support more favorable phenotypes such as memory-like T cells, and stabilize batch-to-batch performance. These improvements are intended to lower cost per dose by reducing failed or underperforming batches, limiting rework, and optimizing cytokine and reagent usage, while also shortening development timelines by reducing trial-and-error media tuning.
“As cell therapies advance, customers need partners who provide both high-quality raw materials and pathways to process optimization,” said Robert Perry, Chief Scientific Officer at GeminiBio. “aiMOS builds on our industry-leading position in human AB serum and expands our ability to help developers improve CQAs and reduce manufacturing risk, backed by the documentation and support required for clinical and commercial success.”
